Lung Cancer | Benjamin Levy, MD and Raymond Lobins, DO

published 2 weeks ago by Dr Neil Love

Visiting Professors: Lung Cancer Edition — Part 1: Our discussion with Drs Levy and Lobins highlights the following topics as well as cases from Dr Lobins’s practice: Case: A man in his early 60s, a current smoker, with metastatic lung adenocarcinoma and a PD-L1 tumor proportion score (TPS) of 80% experiences a dramatic response to first-line pembrolizumab but a recurrence of small lymphocytic lymphoma (SLL) during therapy (00:00) Activity and tolerability of immune checkpoint inhibitors alone or with chemotherapy as first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC) (02:30) Duration of therapy with immune checkpoint inhibitors (05:28) Perspectives on the effects of recent advances in the management of lung cancer on the practice of oncology (09:16) Potential correlation between recurrence of chronic lymphocytic leukemia or SLL and treatment with anti-PD-1/PD-L1 antibodies (11:02) Case: A woman in her late 50s with a history of autoimmune uveitis is diagnosed with NSCLC and multiple metastases in the brain (13:46) Side effects associated with whole-brain radiation therapy (14:55) Use of immune checkpoint inhibitors for patients with preexisting autoimmune disorders (17:45) Therapeutic options for patients with metastatic NSCLC in the second-line setting (22:05) Results of the Phase III REVEL trial investigating ramucirumab with docetaxel as second-line therapy for patients with metastatic NSCLC (24:16) Activity of ramucirumab in patients with squamous cell NSCLC and those with prior exposure to bevacizumab (25:45) Side effects and tolerability of ramucirumab and bevacizumab (26:46) Case: A man in his early 50s, a current smoker, with metastatic lung adenocarcinoma and a BRAF non-V600E tumor mutation receives first-line carboplatin/pemetrexed/pembrolizumab (29:19) Hemoptysis as a presenting symptom of lung cancer (30:28) Clinical care of patients with metastatic NSCLC and no identified targetable tumor mutations (32:58) Novel agents and approaches under investigation for lung cancer (36:11) Mechanisms of resistance to immunotherapy (39:15) Monitoring for immune-related adverse events in patients receiving immune checkpoint inhibitors (41:31) Case: A woman in her mid-50s with large cell neuroendocrine carcinoma of the lung and a solitary metastasis in the brain (43:20) Perspective on the management of oligometastatic disease (45:55) Therapeutic options for patients with metastatic large cell neuroendocrine carcinoma of the lung (48:10) Management of metastatic small cell lung cancer in the second-line setting (51:07) Case: A man in his early 80s with severe pulmonary fibrosis is diagnosed with metastatic NSCLC (54:40) Challenges in the management of pulmonary fibrosis in elderly patients with lung cancer (58:22) Biologic rationale for and emerging data with immune checkpoint inhibitors in combination with anti-angiogenic agents (1:01:13) Benefits and challenges of integrating early palliative care into the management of metastatic lung cancer (1:03:55) Case: A man in his late 60s with metastatic NSCLC with KRAS and p53 tumor mutations experiences disease progression on multiple lines of therapy (1:06:27) Therapeutic approach for patients with metastatic NSCLC in the late-line setting (1:08:26) Case: A woman in her early 20s initially diagnosed with unresectable Stage III NSCLC with mutations in ROS1 and p53 develops metastatic disease (1:13:22) Activity and tolerability of crizotinib and lorlatinib in patients with metastatic NSCLC and ROS1 tumor mutations (1:15:37) Sequencing therapies for patients with metastatic NSCLC and ROS1 tumor mutations (1:18:23) CME information and select publications  

more episodes from Research To Practice | Oncology Videos